Trifocal IOL implantation to achieve better patient satisfaction: 4 year clinical results and quality of vision

Session Details

Session Title: Pseudophakic IOLs: Multifocal I

Session Date/Time: Monday 12/09/2016 | 08:00-10:30

Paper Time: 09:24

Venue: Auditorium A

First Author: : B.Kusa ITALY

Co Author(s): :    M. Piovella                    

Abstract Details

Purpose:

To evaluate visual and optical performances of cataract eyes after phacoemulsification and trifocal Intraocular Lens (IOL) (AT LISA tri 839MP, Carl Zeiss Meditec) implantation.To demonstrate that a wider number of presbyopic IOLs implants depends from a right selection based mainly on eye selection and not only on patient selection. To demonstrate that a refractive postop range between -0,50sf and +0,50 sf is appropriate to avoid healos and glare patients complains

Setting:

C.M.A. Centro Microchirurgia Ambulatoriale Monza, Italy

Methods:

100 eyes of 60 patients mean age: 67.28 ± 11.59 years underwent uncomplicated phacoemulsification and trifocal IOL (AT LISA tri839MP, Carl Zeiss Meditec) implantation. Preloaded IOL was implanted using a BLUEMIXS 180 injector. Postoperatively, the following visual and refractive parameters were measured: distance (5m) near (40cm) and intermediate (80 cm) visual acuity, corneal topography and aberrometry, contrast sensitivity and defocus curve. Regular follow-up examinations were performed up to 4 years after surgery.

Results:

Preoperative distance UCVA was 20/126 ± 72.87. At 4 years, distance UCVA is 20/25 ± 30.40 , monocular and binocular uncorrected near vision are 20/23. Monocular uncorrected intermediate vision is 20/32, binocular uncorrected intermediate vision is 20/26. We have not explanted any IOLs. 93% of our patients have a refractive post operative results within -0,50 sf and +0.50 sf almost in one eye.

Conclusions:

AT LISA tri 839MP provided satisfactory distance and near as well as intermediate visual acuity. This lens also improved quality of vision through remarkable diffraction efficiency while maintaining contrast sensitivity.

Financial Disclosure:

... receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented, ... travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented